| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $2,068 | 1 | 5 |
Sells | $1,598,191 | 19 | 95 |
| AULT MILTON C III | 1 | $2,068 | 18 | $1.59M | $-1.59M | |
| Horne William B. | director | 0 | $0 | 1 | $7,059 | $-7,059 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Over the last 12 months, insiders at Alzamend Neuro Inc have bought $2,068 and sold $1.6M worth of Alzamend Neuro Inc stock.
On average, over the past 5 years, insiders at Alzamend Neuro Inc have bought $1.07M and sold $781,174 worth of stock each year.
Highest buying activity among insiders over the last 12 months: AULT MILTON C III () — $2,068.
The last purchase of 2,000 shares for transaction amount of $2,068 was made by AULT MILTON C III (director) on 2026‑04‑14.
| 2026-08-26 | Sale | AULT MILTON C III | director | 2,000 0.049% | $1.56 | $3,116 | -0.60% | |
| 2026-04-14 | AULT MILTON C III | director | 2,000 0.073% | $1.03 | $2,068 | +15.38% | ||
| 2025-12-23 | Sale | AULT MILTON C III | director | 1,851 0.058% | $2.07 | $3,825 | -33.82% | |
| 2025-12-19 | Sale | Horne William B. | director | 3,333 0.1065% | $2.12 | $7,059 | -35.07% | |
| 2025-10-09 | Sale | AULT MILTON C III | director | 20,397 0.6478% | $2.32 | $47,390 | -28.33% | |
| 2025-10-08 | Sale | AULT MILTON C III | director | 101,394 3.1113% | $2.44 | $247,158 | -33.40% | |
| 2025-10-07 | Sale | AULT MILTON C III | director | 57,379 1.8285% | $2.49 | $142,954 | -31.73% | |
| 2025-10-06 | Sale | AULT MILTON C III | director | 82,033 2.5039% | $2.45 | $201,268 | -33.59% | |
| 2025-10-03 | Sale | AULT MILTON C III | director | 65,903 2.153% | $2.44 | $160,889 | -32.81% | |
| 2025-10-02 | Sale | AULT MILTON C III | director | 20,686 0.6627% | $2.39 | $49,522 | -29.55% | |
| 2025-10-01 | Sale | AULT MILTON C III | director | 36,777 1.1559% | $2.35 | $86,378 | -27.35% | |
| 2025-09-30 | Sale | AULT MILTON C III | 3,566 0.1113% | $2.33 | $8,321 | -24.79% | ||
| 2025-09-29 | Sale | AULT MILTON C III | 38,324 1.1942% | $2.31 | $88,490 | -23.73% | ||
| 2025-09-26 | Sale | AULT MILTON C III | 37,738 1.1543% | $2.31 | $87,345 | -24.90% | ||
| 2025-09-25 | Sale | AULT MILTON C III | 14,628 0.4527% | $2.31 | $33,829 | -22.88% | ||
| 2025-09-24 | Sale | AULT MILTON C III | 39,140 1.2094% | $2.31 | $90,374 | -23.32% | ||
| 2025-09-23 | Sale | AULT MILTON C III | 43,238 1.3951% | $2.38 | $102,721 | -22.13% | ||
| 2025-09-19 | Sale | AULT MILTON C III | 77,009 2.4% | $2.35 | $180,856 | -23.75% | ||
| 2025-09-18 | Sale | AULT MILTON C III | 20,870 0.6586% | $2.47 | $51,493 | -25.90% | ||
| 2025-09-17 | Sale | AULT MILTON C III | 2,121 0.0663% | $2.45 | $5,204 | -25.60% |
| AULT MILTON C III | director | 0 0% | $0 | 109 | 29 | <0.0001% |
| Horne William B. | director | 0 0% | $0 | 3 | 1 | |
| GUSTAFSON MARK | 60000 1.577% | $99,600.00 | 0 | 2 | ||
| Jackman Stephan | Chief Executive Officer | 45500 1.1959% | $75,530.00 | 1 | 0 | |
| McGrath Lynne Fahey | director | 10000 0.2628% | $16,600.00 | 1 | 1 | |
| Katzoff David J | Chief Financial Officer | 5540 0.1456% | $9,196.40 | 2 | 0 |
$6,934,920 | 41 | -9.19% | $6.83M | |
Alzamend Neuro, Inc. (ALZN) | $13,664,154 | 40 | -70.35% | $6.32M |
$63,749,694 | 24 | -12.24% | $3.98M | |
$37,200,153 | 21 | -47.67% | $7.49M | |
$287,718 | 15 | -41.45% | $8.46M | |
$11,777,042 | 10 | -11.94% | $6.57M | |
$13,595,542 | 9 | -16.74% | $7.97M | |
$108,996 | 8 | -33.42% | $6.64M | |
$192,099 | 7 | -39.17% | $5.7M | |
$40,324 | 6 | 31.82% | $5.5M | |
$147,504 | 5 | -36.70% | $4.35M | |
$726,438 | 4 | -72.85% | $7M | |
$1,184,658 | 4 | -22.17% | $5.08M | |
$76,299 | 4 | 11.60% | $7.6M | |
$14,530 | 3 | 62.23% | $5.63M | |
$1,057,000 | 3 | 5.27% | $4.11M | |
$16,526,031 | 2 | -0.85% | $8.17M | |
$3,309,940 | 2 | -5.66% | $3.85M | |
$75,000 | 1 | -30.67% | $6.1M |
| Increased Positions | 8 | +114.29% | 98,027 | +66.4% |
| Decreased Positions | <1 | -14.29% | <1 | <0.01% |
| New Positions | 3 | New | 43,052 | New |
| Sold Out Positions | <1 | Sold Out | <1 | Sold Out |
| Total Postitions | 14 | +100% | 245,648 | +66.4% |
| Drw Securities, Llc | $173.00 | 2.28% | 91,245 | +91,245 | New | 2025-09-30 |
| Vanguard Group Inc | $41.00 | 0.54% | 21,620 | +21,620 | New | 2025-09-30 |
| Geode Capital Management, Llc | $39.00 | 0.51% | 20,578 | +20,578 | New | 2025-09-30 |
| Clearstead Advisors, Llc | $19.00 | 0.25% | 10,000 | +10,000 | New | 2025-09-30 |
| Ubs Group Ag | $4.00 | 0.05% | 2,075 | +1,173 | +130.04% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $3.00 | 0.04% | 1,606 | +809 | +101.51% | 2025-09-30 |
| Blackrock, Inc. | $1.00 | 0.01% | 437 | -4 | -0.91% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 37 | +18 | +94.74% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 22 | 0 | 0% | 2025-09-30 |
| Citigroup Inc | $0 | 0% | 1 | +<1 | New | 2025-09-30 |